Misti® began with the lived reality of respiratory care: when breathing becomes difficult, treatment needs to feel simple, reliable and within reach.
For too many patients and caregivers, that is not always the case. Inhaled therapy can be stressful, inconsistent and hard to complete, especially when patients are young, elderly, unwell, anxious, neurodiverse or already struggling to breathe.
Misti® was shaped by that reality.
Founder Dr Anushi Rajapaksa brings together personal experience, biomedical engineering expertise and a deep commitment to paediatric technology. The company’s mission is grounded in a simple but urgent belief: respiratory treatment should work in real life, not only in ideal conditions.
This is not technology for technology’s sake.
It is a company built around the belief that better delivery can change what care feels like for patients, caregivers, clinicians and future therapeutic partners.
Misti® exists because the delivery of medicine should not create more burden for people who are already struggling to breathe.
Mission
To provide rapid respiratory care anywhere, anytime using a hospital grade smart inhaler.
Vision
To become the global leader in wearable biologics inhalation.
What this means
Misti® starts with more usable respiratory care and expands towards advanced pulmonary delivery for the future of medicine.
The first application is MedMisti™, a wearable, breath actuated smart inhalation system for respiratory care.
The broader ambition is a pulmonary delivery platform that can support future pathways across biologics, RNA based medicines and other advanced inhaled therapeutics.
Dr. Anushi Rajapaksa’s mission to transform respiratory care began the day she carried her young son into the Emergency Department, struggling to breathe.
As a biomedical scientist and engineer, Anushi was already researching new approaches to respiratory drug delivery. But repeated hospital visits with her son gave that work a new urgency. While many parents spent their child’s early years navigating playgrounds and school routines, Anushi spent hers holding her son through respiratory crises, watching monitors and waiting for the next round of treatment.
Those experiences revealed a problem she could not ignore: even the most effective medicines cannot help patients if they are not delivered efficiently, reliably and in a way they can tolerate.
That realisation became the catalyst for Misti®.
Today, Anushi combines more than a decade of scientific research with lived experience as a mother and caregiver. She leads Misti® with a clear and urgent goal: to transform inhaled therapy so vulnerable patients can receive effective respiratory care wherever and whenever they need it.
See how Anushi’s mission became the Misti® platform.
Pulmonary delivery is a hard problem. It requires more than one type of expertise.
Misti® brings together biomedical engineering, respiratory product design, public health, general practice, acoustofluidics, governance, regulatory strategy and medtech translation.
Leadership and advisory strength includes
The strength of the team is not only technical. It is the combination of people who understand the science, the patient experience and the pathway from idea to real world care.
Medical device translation requires more than a promising idea.
It requires scientific credibility, engineering discipline, commercialisation support, intellectual property strategy, regulatory planning and a pathway towards manufacturability.
Misti’s development has been supported by a broader research, engineering and commercialisation ecosystem.
These relationships help Misti® move beyond concept and towards practical medical device development, validation and commercial translation.
MedMisti™ is the first real world application, but Misti’s ambition is broader.
The company is developing a pulmonary delivery platform that can begin in respiratory care and expand towards biologics, mRNA therapeutics and future advanced inhaled medicines.
The current application provides focus.
The platform creates future potential.
That distinction matters because the delivery challenge is not limited to one condition, one medicine or one care setting.
Across respiratory care, pharmaceutical development, public health and future field based use, the same question keeps returning:
Can medicine reach the lungs reliably, visibly and in a way people can actually use?
Misti® is being built around that question.
Misti’s approach is shaped by the belief that drug delivery should respond to the patient, not the other way around.
Misti® designs around people who may struggle with traditional treatment, including children, elderly patients, neurodiverse patients and people with compromised respiratory capacity.
The platform focuses on how, when and whether medicine moves with the breath, not just whether aerosol can be generated in controlled conditions.
Misti® is being developed with usability, regulation, manufacturability, partner readiness and future therapeutic pathways in mind.
This is how Misti® connects human need with scientific possibility.
Misti’s credibility is built across research, technical development, usability insight, IP activity and regulatory planning.
Key credibility signals
Early MedMisti™ feedback has shown encouraging signals, including preference over traditional spacer use and reported comfort from participants in a pre pilot usability study.
These signals do not mean the work is finished.
They show that Misti® is building from a serious foundation.
Misti® is progressing through technical validation, usability refinement, device development, quality system planning, regulatory pathway planning and strategic partner engagement.
The next stage is about turning the scientific foundation into manufacturable, validated and commercially relevant pulmonary delivery solutions.
The goal is clear: move from early validation towards real world respiratory care and future pulmonary delivery applications.
Misti® is building a mesh free pulmonary delivery platform for patients, clinicians, pharmaceutical partners and health systems that need better ways to move medicine through the lungs.
The first application is MedMisti™.
The broader ambition is a future where inhaled therapy is easier to use, easier to track and better suited to advanced medicine.
Find answers about how MedMisti™ works and what it can do for you
Misti® is a pulmonary drug delivery company developing mesh free, breath actuated technology to make inhaled therapy more reliable, more usable and better suited to future medicine.
Misti® was founded to address the real world challenge of respiratory treatment. For many patients, inhaled therapy can be difficult to use, poorly aligned with natural breathing behaviour and hard to track outside the clinic.
Misti® was founded by Dr Anushi Rajapaksa, a biomedical engineer with expertise in paediatric technology, acoustofluidics and medtech innovation.
Misti® is building a pulmonary delivery platform that uses mesh free aerosol generation, breath actuated delivery and connected treatment visibility to support more reliable inhaled therapy.
MedMisti™ is the first real world application of Misti’s pulmonary delivery platform. It is a wearable, breath actuated smart inhalation system designed for respiratory care.
Misti’s broader vision is to become a global leader in wearable biologics inhalation, beginning with respiratory care and expanding towards future advanced pulmonary delivery applications.
Misti® brings together expertise across biomedical engineering, respiratory product design, public health, primary care, acoustofluidics, governance, regulatory strategy and medtech translation.
Partners can engage through investment, pharmaceutical collaboration, clinical or usability research, manufacturing and distribution pathways, public health partnerships or strategic commercial conversations.
